Parker Institute retweeted
Honored to moderate a fantastic panel on a key bottleneck in #celltherapy @parkerici @US_FDA @AllogeneTx @AstraZeneca @IovanceBio
Parker Institute retweeted
Last chance to register! Join us Wednesday in DC or virtually for our "Unlocking Next-Generation Therapies" meeting: bit.ly/4sZadyf. This free event will bring together experts across industries to explore innovative approaches in cell therapy development.
Parker Institute retweeted
Fantastic collaboration between @GuardantHealth and @parkerici Methyl-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study aacrjournals.org/cancerresco…
Parker Institute retweeted
At #SITC25 Ira Mellman of the @parkerici and Medici Therapeutics will be honored for the 2025 Richard V. Smalley Memorial Award and Lectureship! He will give a presentation on Nov. 8 – join virtually or attend in person. sitcancer.org/2025/home
Parker Institute retweeted
Collection highlight from @Cancer_Cell: Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy
hubs.li/Q03x0gSB0
@PennMedicine
Parker Institute retweeted
With solid tumors representing ~90% of cancers, Dispatch Bio is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform to help create a world where all #cancer patients can be cured. Learn more: dispatchbio.com/news/dispatc…
Parker Institute retweeted
Startup Dispatch Bio has ambitious plan, research superstars and $216 million to battle cancer
bizjournals.com/sanfrancisco…
Parker Institute retweeted
Dispatch Bio raises $216 million for solid tumor immunotherapy
Solid tumors have challenged CAR-T developers
Sean Parker, ARCH launch biotech developing a universal immunotherapy statnews.com/2025/07/23/sean…
Parker Institute retweeted
Parker Institute, ARCH unveil CAR-T biotech with $216M to crack solid tumors endpoints.news/parker-instit…
Parker Institute retweeted
Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy | BioPharma Dive biopharmadive.com/news/dispt…
Parker Institute retweeted
In the latest issue! Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias dlvr.it/TLcGmQ
Parker Institute retweeted
We’re proud to announce that Elizabeth Mittendorf, MD, will join BIDMC as Chief of a new Division of Breast Surgery! 👏 A renowned surgeon, she will bring bold leadership to our growing program in collaboration with Dana-Farber. Learn more: bidmc.org/about-bidmc/news/2…
Parker Institute retweeted
𝐂𝐀𝐑-𝐓 𝐋𝐨𝐠𝐢𝐜-𝐆𝐚𝐭𝐢𝐧𝐠: @ArsenalBio CEO @KDrazan describes the idea of logic-gating, which might allow CAR-T therapies to work in solid tumors when targeting more than one antigen is needed.
Full interview: biotechtv.com/post/arsenalbi…
Parker Institute retweeted
Share your #cancer #immunology research w/ #CSCancerImmunity2025 organizers Ignacio Melero @unav, Ira Mellman @parkerici, Fabiola Rivas, @ImmunityCP & Montse Rojo de la Vega @Cancer_Cell. Abstract deadline July 25 hubs.li/Q03tjTxS0
Parker Institute retweeted
Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy (@parkici), asks why so many drug developers are retreating from cancer immunotherapies before they have achieved their full potential in our latest interview nature.com/articles/d41573-0…
Parker Institute retweeted
New #JITC review: Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials bit.ly/4dTQf0V @John_E_Connolly
Parker Institute retweeted
thank you, @CancerResearch -- we are fired up and ready to make some bold moves
🌟 Meet the 2025 Lloyd J. Old STARs- five extraordinary rising scientific leaders whose work is pushing the boundaries of what’s possible in cancer immunotherapy! Discover: bit.ly/4kFIjmo #CancerResearch #Immunotherapy (1/2)
Parker Institute retweeted
Here's our latest, led by superstars @JoYatesResearch & Dr. Camille Mathey-Andrews, jointly with @val_boeva and many more @DanaFarberNews @broadinstitute
We studied primary & lethal esophageal cancer using multi[RNA, ATAC, spatial]-omics, see Josephine's tweets below for more!👇
Thrilled to share our new paper out today in Cell Reports Medicine! @VanAllenLab @val_boeva We map cell states & neighborhoods across clinical stages of esophageal adenocarcinoma (EAC) using single-cell, epigenomic & spatial data.🔗cell.com/cell-reports-medici… (1/9)
Parker Institute retweeted
Spectacular work from @parkerici investigator @MarcelaMaus IFN-γ–resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models | STM @MassGenBrigham #CellTherapy science.org/doi/10.1126/scit…
Parker Institute retweeted
🚨 New Preprint 🚨
A continuous landscape of signaling encodes a corresponding landscape of CAR T cell phenotype
How can we tune JAK/STAT signaling to create better immune cell therapies?
doi.org/10.1101/2025.06.05.6…



























